S4 Ep50: Saba Spotlights the Nuances of Treating Nasopharygeal Cancer
S4 Ep49: Research Reflections: Sonpavde on Urothelial Cancer Updates From the 2021 GU Cancers Symposium
S4 Ep48: FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma
S4 Ep47: FDA Approval Insights: Trilaciclib in Extensive-Stage Small Cell Lung Cancer
S4 Ep46: Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research
S4 Ep45: The Marshalls Open a Candid Conversation About Cancer
S4 Ep44: Hu Highlights Recent Advances and Approvals in RET-Altered Thyroid Cancer
S4 Ep43: Coleman and Brown Review Advancing Applications for PARP Inhibition in Ovarian Cancer
S4 Ep42: Borgen Breaks Down the Domino Effect of Expanded Education and Banished Stigmas in Male Breast Cancer
S4 Ep41: Monk and Herzog Hammer Out PARP Nuances in Ovarian Cancer
S4 Ep40: Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC
S4 Ep39: Levy Lauds Biomarker-Driven Data in Lung Cancer
S4 Ep38: FDA Approval Insights: Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer
S4 Ep37: Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC
S4 Ep36: FDA Approval Insights: Tepotinib in METex14-Altered Metastatic NSCLC
S4 Ep35: Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers
S4 Ep34: Nichols on Navigating the Nuances of von Hippel-Lindau Disease
S4 Ep33: Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer
S4 Ep32: Schilsky and Gralow Share Advice for ASCO Leadership and Therapeutic Equity in Cancer
S4 Ep31: Klempner Keys in on the Pan-Tumor Potential of Seribantumab in NGR1+ Solid Tumors
S4 Ep30: Marvels in Medicine: Dr. Slamon on a Career of Drug Development in Oncology
S4 Ep29: Mesa and Gerds Talk Management Strategies and Emerging Agents in Myelofibrosis
S4 Ep27: Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC
S4 Ep28: Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC
S4 Ep26: Markman Talks Vilified Vaccines, Taboos, and Treatment for Cervical Cancer
S4 Ep25: FDA Approval Insights: Nivolumab/Cabozantinib in Advanced RCC
S4 Ep24: Forecasting Future Advances Across Oncology
S4 Ep23: Pursuing New Paradigms in Prostate Cancer
S4 Ep22: Powles and Rini Put ctDNA Into Perspective in Urothelial Cancer
S4 Ep21: Braunstein and Richter Talk Transplant and Therapy Options in Newly Diagnosed Myeloma
S4 Ep20: Spotlighting Management Strategies Across Sarcoma Subtypes
S4 Ep19: Lindau on Leading Successful Surgical Fellowships
S4 Ep18: Gaining Insight Into the Management of Gastrointestinal Malignancies
S4 Ep17: Druker Details a Career of Determination, Patient Impact, and Family Success
S4 Ep16: Multimodality Therapy Makes Waves in Bladder Cancer
S4 Ep15: Borghaei and Gunuganti Break Down the Elements of Treatment Selection in NSCLC
S4 Ep14: Learning to Tailor Targeted and Immune Therapy in Lung Cancer
S4 Ep13: Bardia Brings to Light Complex Breast Cancer Cases
S4 Ep12: Robert Recaps a Career of Clinical Research in Melanoma
S4 Ep11: Huntsman Homes in on the Integration of Precision Medicine in Oncology
S4 Ep10: Marvels in Medicine: Dr. Karlan on Creating Continuous Quality Improvement in Gynecologic Oncology
S4 Ep9: Loaiza-Bonilla on Applications, Actionability, and Affordability of AI in Oncology
S4 Ep8: Oxnard on Opening the Door for Precision Medicine in Lung Cancer
S4 Ep7: Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis
S4 Ep6: Raez Raises Concerns Over Delayed Cancer Care in the COVID-19 Era
S4 Ep5: Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer
S4 Ep4: Aggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer Armamentarium
S4 Ep3: Tripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast Cancer
S4 Ep2: Lyman on Bringing Biosimilars From Bench to Bedside in Oncology
S4 Ep1: Raez on the Rise of Liquid Biopsy in Lung Cancer
next page